First in China: SC-101, a Peptide Drug Conjugate (PDC), has been approved by the Chinese National Medical Products Administration.

On January 2, 2024, the company's first Peptide-Drug Conjugate (PDC), SC-101, was approved by the Chinese National Medical Products Administration for the treatment of patients with malignant solid tumors that expressed Nectin-4. 

SC-101 is a peptide-drug conjugate, which consists of a cell-targeting peptide that targets the human Nectin-4 protein, and a microtubule inhibitor, MMAE, that conjugats by a protease-hydrolyzable linker. Conjustar will accelerate the clinical trial to verify the efficacy of SC-101 in cancer patients and to provide a more effective, safer, and more accessible innovative therapy for patients with advanced tumor that express Nectin-4 earlier.